Personalized Exercise Treatments for Older Veterans With Motoric Cognitive Risk Syndrome

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age65+
SponsorVA Office of Research and Development

About this trial

This study will begin to evaluate personalized preventative dementia treatments for Veterans at risk for developing dementia. The investigators will target Veterans with Motoric Cognitive Risk syndrome (MCR), which is characterized by slow gait speed and cognitive concerns (e.g., problems with memory or concentrations).

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age 65

Receiving VA primary care

Community-dwelling

Motoric Cognitive Risky Syndrome i. Slow gait speed ii. Subjective cognitive concerns/complaints

Disqualifiers

Non-English speaking

Presence of a terminal disease

Major medical problem

Myocardial infarction or major surgery in the previous 3 months

Trial design

Design model

Sequential

Treatments tested in this trial

  • Functional Power Training (FPT)

    Behavioral

    Participants will receive twice weekly FPT, a progressive functional-based exercises that target optimizing leg force production and leg velocity.

  • Music-Based Digital Therapy (MBDT)

    Behavioral

    Participants will receive twice weekly MBDT, a technology-driven gait training that is grounded in evidence-based rehabilitation treatment, rhythmic auditory stimulation.

  • FPT + MBDT

    Behavioral

    For non-responders who were randomized to augment treatment, they will receive combined FPT and MBDT treatment.

Treatment groups

54 Participants
are divided into 2 treatment groups
Group A: Stage 1 Exercise TreatmentExperimental treatment 2 interventions
Group B: Stage 2: Exercise TreatmentExperimental treatment 3 interventions

Trial outcomes

Primary outcomes

1

Enrollment/Baseline

Enrollment will be defined as the number of participants who were recruited and consented to the study.

Time frame
Enrollment
2

Retention

Retention will be defined as the number of participants who completed the 12-week exercise treatment.

Time frame
Baseline to end of 12-week treatment
3

Compliance

Compliance will be defined by the proportion of completed treatment sessions.

Time frame
Baseline to end of 12-week treatment
4

Acceptability

Acceptability will be recorded by conducting interviews with participants who completed the 12-week exercise treatment.

Time frame
End of 12-week treatment

Secondary outcomes

1

Gait Speed

Change in gait speed will be assessed after 12-week exercise treatment.

Time frame
Baseline to end of 12-week treatment

Other outcomes

1

Cognition - Executive Function

Change in executive function will be assessed after 12-week exercise treatment using Delis-Kaplan Executive Function System.

Time frame
Baseline to end of 12-week treatment

Sponsors and contacts

Click on the lead sponsor to view all of their trials.